vs
KFORCE INC（KFRC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
KFORCE INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.6倍（$330.4M vs $207.3M），KFORCE INC净利率更高（2.4% vs -62.0%，领先64.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 0.1%），KFORCE INC自由现金流更多（$-7.4M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -3.7%）
Kforce Inc.是一家总部位于美国的专业人力资源服务与解决方案供应商，业务覆盖技术、财务会计、医疗保健三大核心领域，为全美各类中大型企业提供专业人才派遣、劳动力管理优化等定制服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
KFRC vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $330.4M | $207.3M |
| 净利润 | $7.9M | $-128.6M |
| 毛利率 | 27.3% | — |
| 营业利润率 | 3.6% | -54.7% |
| 净利率 | 2.4% | -62.0% |
| 营收同比 | 0.1% | 25.9% |
| 净利润同比 | -2.7% | 3.5% |
| 每股收益（稀释后） | $0.46 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $330.4M | — | ||
| Q4 25 | $332.0M | $207.3M | ||
| Q3 25 | $332.6M | $159.9M | ||
| Q2 25 | $334.3M | $166.5M | ||
| Q1 25 | $330.0M | $139.3M | ||
| Q4 24 | $343.8M | $164.6M | ||
| Q3 24 | $353.3M | $139.5M | ||
| Q2 24 | $356.3M | $147.0M |
| Q1 26 | $7.9M | — | ||
| Q4 25 | $5.2M | $-128.6M | ||
| Q3 25 | $11.1M | $-180.4M | ||
| Q2 25 | $10.4M | $-115.0M | ||
| Q1 25 | $8.1M | $-151.1M | ||
| Q4 24 | $11.1M | $-133.2M | ||
| Q3 24 | $14.2M | $-133.5M | ||
| Q2 24 | $14.2M | $-131.6M |
| Q1 26 | 27.3% | — | ||
| Q4 25 | 27.2% | — | ||
| Q3 25 | 27.7% | — | ||
| Q2 25 | 27.1% | — | ||
| Q1 25 | 26.7% | — | ||
| Q4 24 | 27.0% | — | ||
| Q3 24 | 27.9% | — | ||
| Q2 24 | 27.8% | — |
| Q1 26 | 3.6% | — | ||
| Q4 25 | 2.6% | -54.7% | ||
| Q3 25 | 4.5% | -106.9% | ||
| Q2 25 | 4.5% | -64.8% | ||
| Q1 25 | 3.5% | -102.6% | ||
| Q4 24 | 4.5% | -74.3% | ||
| Q3 24 | 5.3% | -94.6% | ||
| Q2 24 | 5.5% | -79.1% |
| Q1 26 | 2.4% | — | ||
| Q4 25 | 1.6% | -62.0% | ||
| Q3 25 | 3.3% | -112.8% | ||
| Q2 25 | 3.1% | -69.0% | ||
| Q1 25 | 2.5% | -108.5% | ||
| Q4 24 | 3.2% | -80.9% | ||
| Q3 24 | 4.0% | -95.7% | ||
| Q2 24 | 4.0% | -89.5% |
| Q1 26 | $0.46 | — | ||
| Q4 25 | $0.29 | $-1.28 | ||
| Q3 25 | $0.63 | $-1.81 | ||
| Q2 25 | $0.59 | $-1.17 | ||
| Q1 25 | $0.45 | $-1.57 | ||
| Q4 24 | $0.60 | $-1.34 | ||
| Q3 24 | $0.75 | $-1.40 | ||
| Q2 24 | $0.75 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $117.4M | $-80.0M |
| 总资产 | $384.8M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $1.3M | — | ||
| Q4 25 | $2.1M | $421.0M | ||
| Q3 25 | $1.3M | $202.5M | ||
| Q2 25 | $2.5M | $176.3M | ||
| Q1 25 | $444.0K | $127.1M | ||
| Q4 24 | $349.0K | $174.0M | ||
| Q3 24 | $127.0K | $150.6M | ||
| Q2 24 | $110.0K | $480.7M |
| Q1 26 | $117.4M | — | ||
| Q4 25 | $124.6M | $-80.0M | ||
| Q3 25 | $132.1M | $9.2M | ||
| Q2 25 | $134.4M | $151.3M | ||
| Q1 25 | $138.0M | $144.2M | ||
| Q4 24 | $154.6M | $255.0M | ||
| Q3 24 | $167.4M | $346.8M | ||
| Q2 24 | $166.6M | $432.4M |
| Q1 26 | $384.8M | — | ||
| Q4 25 | $365.6M | $1.5B | ||
| Q3 25 | $374.2M | $1.2B | ||
| Q2 25 | $373.6M | $1.3B | ||
| Q1 25 | $368.2M | $1.3B | ||
| Q4 24 | $357.8M | $1.5B | ||
| Q3 24 | $369.9M | $1.5B | ||
| Q2 24 | $362.7M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-7.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | -2.2% | -48.6% |
| 资本支出强度资本支出/营收 | 1.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $19.7M | $-99.8M | ||
| Q3 25 | $23.3M | $-91.4M | ||
| Q2 25 | $18.4M | $-108.3M | ||
| Q1 25 | $249.0K | $-166.5M | ||
| Q4 24 | $21.8M | $-79.3M | ||
| Q3 24 | $31.0M | $-67.0M | ||
| Q2 24 | $20.9M | $-77.0M |
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $16.7M | $-100.8M | ||
| Q3 25 | $19.8M | $-92.7M | ||
| Q2 25 | $14.2M | $-110.7M | ||
| Q1 25 | $-3.9M | $-167.8M | ||
| Q4 24 | $20.9M | $-79.5M | ||
| Q3 24 | $27.5M | $-68.6M | ||
| Q2 24 | $17.8M | $-79.0M |
| Q1 26 | -2.2% | — | ||
| Q4 25 | 5.0% | -48.6% | ||
| Q3 25 | 6.0% | -58.0% | ||
| Q2 25 | 4.3% | -66.5% | ||
| Q1 25 | -1.2% | -120.5% | ||
| Q4 24 | 6.1% | -48.3% | ||
| Q3 24 | 7.8% | -49.2% | ||
| Q2 24 | 5.0% | -53.7% |
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 1.1% | 0.8% | ||
| Q2 25 | 1.2% | 1.5% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 1.0% | 1.2% | ||
| Q2 24 | 0.9% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | — | ||
| Q3 25 | 2.11× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 1.97× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 1.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KFRC
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
